April 9, 2020         
Neighborhood Pediatrics Practice In Atlanta Remains Open For Patients During COVID-19 Crisis   •   For the First Time, DoubleTree by Hilton Reveals Official Chocolate Chip Cookie Recipe So Bakers Can Create the Warm, Welcoming   •   Nintendo Download: Eggs Mark the Spot in Animal Crossing: New Horizons!   •   Keep Maintaining Your Vehicle Even If It Sits Idle   •   Liberty Global Announces Creation of $4 Million COVID-19 Employee Assistance Fund   •   Demand for Affordable Emergency One-to-One Childcare for America's Essential Workforce Answered by Expert Childcare Consortium   •   Merck Announces $3M Commitment to Address Critical Maternal Health Needs During COVID-19 Pandemic   •   First Book's Covid-19 Action Response Fueled by Generosity of Publishing and Product Partners   •   Branford Community Foundation (BCF) Establishes COVID-19 Response Fund to Enable Grants from Women & Family Life Center (W&a   •   Little Spurs Remains Open And Adds Telemedicine During COVID-19 Pandemic   •   New Study: Majority of Americans Believe Stores Should Reopen by End of May, 2020   •   UPDATE Delivery of 2020 Census Paper Questionnaires Begin   •   Teachers and Staff Join to Connect with Students Artistically - a Virtual Talent Show Keeps a School Community Together   •   BRAVADA International Provides Full Year 2020 Outlook and Update to Shareholders on its Business     •   SurveyVitals Releases National COVID-19 ‘Patient Views’ Report   •   New Consumer Research from Alpha: Only 45% of Consumers Say That Accessing Cash is Important Right Now; Understanding How to Bes   •   Local Pastors Join Citizens for a Pro-Business Delaware In Urging Governor Carney for Racial Breakdown in State Coronavirus Case   •   Convo provides Access to Communication with ASL Interpreting for White House Press Conferences, @Home Interpreting in response t   •   STATEMENT: Listos California on New Advertising Campaign with Trusted Partner Univision   •   YouCam Makeup Extends Hours for Live Shows and Beauty Advisor 1-on-1 Consultations to Meet Record High Activity as Users Stay Ho
Bookmark and Share

TherapeuticsMD Announces Participation at the Cowen 40th Annual Healthcare Conference

BOCA RATON, Fla. , February 27 /Businesswire/ - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Cowen 40th Annual Healthcare Conference in Boston. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.

Details for the presentation include:

Conference

Cowen 40th Annual Healthcare Conference

Date

Tuesday, March 3, 2020

Time

10:00 a.m. Eastern time

A live webcast and replay of the presentation can be accessed on the company’s website, www.therapeuticsmd.com, on the Home Page or under the “Investors & Media” section.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, BIJUVA® and its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility, including the conditions to draw an additional tranche thereunder and whether the lender will make such tranche available; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letter the company received regarding IMVEXXY; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at it website: www.therapeuticsmd.com/pressreleases.aspx.


STORY TAGS: Conference, Webcast, United States, North America, Florida, Women, Consumer, Health, Pharmaceutical, Baby/Maternity,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News